GlassScriptPhysician profile
William B Knight
NPI 1356621890
$12,575.79
in general payments reported to CMS, 2019-2025
51 companies · $1,810 in 2025
The $1,810 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,226 · 2020: $1,075 · 2021: $1,987 · 2022: $1,973 · 2023: $1,959 · 2024: $1,545 · 2025: $1,810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,314.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,451.99 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,362.00 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,135.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $1,049.44 | 2019-2025 | |
| Glaxosmithkline, LLC. | $833.41 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $788.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $715.71 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $692.64 | 2019-2023 | Xarelto |
| Pfizer INC. | $520.11 | 2019-2025 | |
| Esperion Therapeutics, INC. | $468.84 | 2020-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $417.78 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.96 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $355.49 | 2021-2025 | |
| Allergan, INC. | $299.22 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $285.46 | 2021-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.